Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1957 1
1959 2
1964 1
1968 1
1972 1
1974 3
1975 6
1976 7
1977 9
1978 5
1979 9
1980 2
1981 8
1982 10
1983 11
1984 3
1985 9
1986 11
1987 4
1988 13
1989 10
1990 22
1991 14
1992 14
1993 23
1994 37
1995 35
1996 42
1997 45
1998 54
1999 80
2000 106
2001 108
2002 120
2003 155
2004 188
2005 214
2006 323
2007 384
2008 330
2009 405
2010 357
2011 422
2012 405
2013 437
2014 510
2015 551
2016 526
2017 507
2018 476
2019 473
2020 596
2021 612
2022 564
2023 458
2024 223

Text availability

Article attribute

Article type

Publication date

Search Results

8,618 results

Results by year

Filters applied: . Clear all
Page 1
Age-related macular degeneration therapy: a review.
Ammar MJ, Hsu J, Chiang A, Ho AC, Regillo CD. Ammar MJ, et al. Curr Opin Ophthalmol. 2020 May;31(3):215-221. doi: 10.1097/ICU.0000000000000657. Curr Opin Ophthalmol. 2020. PMID: 32205470 Review.
PURPOSE OF REVIEW: The purpose of this review is to describe the current clinical landscape of potential future therapies for both nonexudative (dry) and exudative (wet) age-related macular degeneration (AMD). ...Additional therapeutic breakthroughs will like …
PURPOSE OF REVIEW: The purpose of this review is to describe the current clinical landscape of potential future therapies for both no …
Embryonic Stem Cells in Clinical Trials: Current Overview of Developments and Challenges.
Golchin A, Chatziparasidou A, Ranjbarvan P, Niknam Z, Ardeshirylajimi A. Golchin A, et al. Adv Exp Med Biol. 2021;1312:19-37. doi: 10.1007/5584_2020_592. Adv Exp Med Biol. 2021. PMID: 33159303 Review.
However, this promising field has consistently had remarkable ethical and experimental limitations. This paper is a review of clinical trial studies dealing with hESC and their advantages, limitations, and other specific concerns. Some of the hESC limitations have b …
However, this promising field has consistently had remarkable ethical and experimental limitations. This paper is a review of clinical …
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
CATT Research Group; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. CATT Research Group, et al. N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28. N Engl J Med. 2011. PMID: 21526923 Free PMC article. Clinical Trial.
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. METHODS: …
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular …
THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.
Boyer DS, Schmidt-Erfurth U, van Lookeren Campagne M, Henry EC, Brittain C. Boyer DS, et al. Retina. 2017 May;37(5):819-835. doi: 10.1097/IAE.0000000000001392. Retina. 2017. PMID: 27902638 Free PMC article. Review.
PURPOSE: Geographic atrophy (GA) is an advanced, vision-threatening form of age-related macular degeneration (AMD) affecting approximately five million individuals worldwide. ...METHODS: Primary literature search on PubMed for GA, complement cascade in age-related …
PURPOSE: Geographic atrophy (GA) is an advanced, vision-threatening form of age-related macular degeneration (AMD) affecting a …
Brolucizumab: First Approval.
Markham A. Markham A. Drugs. 2019 Dec;79(18):1997-2000. doi: 10.1007/s40265-019-01231-9. Drugs. 2019. PMID: 31768932 Review.
Brolucizumab (Beovu()) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and …
Brolucizumab (Beovu()) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being d …
Aflibercept.
Stewart MW, Grippon S, Kirkpatrick P. Stewart MW, et al. Nat Rev Drug Discov. 2012 Mar 30;11(4):269-70. doi: 10.1038/nrd3700. Nat Rev Drug Discov. 2012. PMID: 22460118
In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-rela …
In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothe …
Ranibizumab.
Blick SK, Keating GM, Wagstaff AJ. Blick SK, et al. Drugs. 2007;67(8):1199-206; discussion 1207-9. doi: 10.2165/00003495-200767080-00007. Drugs. 2007. PMID: 17521219 Review.
Well designed, phase III trials in patients with neovascular (wet) age-related macular degeneration (AMD) indicated that monthly intravitreal injections of ranibizumab 0.3 or 0.5 mg for up to 2 years maintained or improved visual acuity to a greater extent than sham …
Well designed, phase III trials in patients with neovascular (wet) age-related macular degeneration (AMD) indicated that month …
Low vision rehabilitation for better quality of life in visually impaired adults.
van Nispen RM, Virgili G, Hoeben M, Langelaan M, Klevering J, Keunen JE, van Rens GH. van Nispen RM, et al. Cochrane Database Syst Rev. 2020 Jan 27;1(1):CD006543. doi: 10.1002/14651858.CD006543.pub2. Cochrane Database Syst Rev. 2020. PMID: 31985055 Free PMC article.
SEARCH METHODS: We searched relevant electronic databases and trials registers up to 18 September 2019. SELECTION CRITERIA: We included randomised controlled trials (RCTs) investigating HRQOL, VRQOL and related outcomes of adults, with an irreversible visual impairment (Wo …
SEARCH METHODS: We searched relevant electronic databases and trials registers up to 18 September 2019. SELECTION CRITERIA: We included r …
'Statins in retinal disease'.
Al-Janabi A, Lightman S, Tomkins-Netzer O. Al-Janabi A, et al. Eye (Lond). 2018 May;32(5):981-991. doi: 10.1038/s41433-018-0066-7. Epub 2018 Mar 20. Eye (Lond). 2018. PMID: 29556012 Free PMC article. Review.
Since immune reactivity has been implicated in a number of retinal diseases, such as uveitis, age-related macular degeneration (AMD) and diabetic retinopathy, there is now a growing body of evidence supporting the beneficial effects of statins in these retinopathies …
Since immune reactivity has been implicated in a number of retinal diseases, such as uveitis, age-related macular degeneration …
Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions.
Guimaraes TAC, Georgiou M, Bainbridge JWB, Michaelides M. Guimaraes TAC, et al. Br J Ophthalmol. 2021 Feb;105(2):151-157. doi: 10.1136/bjophthalmol-2020-316195. Epub 2020 Apr 8. Br J Ophthalmol. 2021. PMID: 32269060 Free PMC article. Review.
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developed world. ...The application of gene therapy approaches for sustained delivery of a range of antiangiogenic proteins has the promise of helping to address the …
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developed world. ...The a …
8,618 results